134 results about "Tryptamines" patented technology

This invention relates to pharmaceutically acceptable tryptamine analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of iron ion detection, and particularly relates to a rapid detection method for ferric ions in water, which comprises the following steps: a fluorescent probe preparation step: taking trihydrate of copper nitrate and tryptamine, adding into a centrifuge tube in sequence, adding ultrapure water, performing ultrasonic dissolution, transferring into a high-pressure reaction kettle, and performing hydrothermal reaction to obtain a fluorescent probe; cooling to room temperature, centrifuging the obtained yellow green solution in a centrifugal machine, and filtering the supernate through a microfiltration membrane to obtain a copper-doped carbon quantum dot CuCDs stock solution, namely the fluorescent probe; analyzing and determining Fe < 3 + >: taking the diluent of the prepared CuCDs solution, adding the diluent into a centrifugal tube containing a Fe < 3 + > standard solution, uniformly mixing, carrying out fluorescent quantitative analysis and detection, and exploring the change rule of the fluorescence intensity ratio of CuCDs; according to the rapid detection method for Fe < 3 + > provided by the invention, the synthesized CuCDs have high sensitivity, can realize on-site rapid detection of Fe < 3 + > in a water medium, and shows a wide application prospect in the field of environmental monitoring.

A method of purifying 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is provided which comprises dissolving crude 5-MeO-DMT in a solvent at a temperature above room temperature, cooling the obtained solution to a temperature below room temperature to precipitate solid 5-MeO-DMT, separating the solid 5-MeO-DMT from the remaining solution and removing solvent from the crystalline 5-MeO-DMT. In the method, the solvent comprises one or more ethers and less than 5 wt % anti-solvent.

This invention belongs to the field of pharmaceutical chemistry, and specifically relates to a compound antifungal cream containing the traditional Chinese medicine ingredient tryptamine ketone and its application. The invention comprises the following components, with the following percentage content: stearic acid 10%~16%, glyceryl monostearate 3%~7%, liquid paraffin 5%~9%, tryptamine 0.1%~0.01%, terbinafine hydrochloride 0.00625%~0.000625%, glycerin 4%, triethanolamine 2%~6%, ethylparaben 0.5%, and the balance being purified water or distilled water. This invention is highly effective, low in toxicity, and exhibits low drug resistance.

The present application belongs to the technical field of pharmaceutical therapy, and particularly relates to an amide-substituted tryptophan ketone derivative, a preparation method and application thereof. The structural formula of the tryptophan ketone derivative is shown in formula (A) or formula (B). In the formula, n=1 or 2, and R is any one of dimethylamine group, diethylamine group, morpholine group, 1-methylpiperazine group, cyclopropylamine group and 4-hydroxypiperidyl group. The compound can selectively inhibit the activity of acetylcholinesterase, and has the potential to develop into a drug for treating Alzheimer's disease due to the abilities of self-aggregation and the like. 1‑42 ​

The invention discloses a method for synthesizing novel alkaloid by enzyme catalysis of tryptamine and alpha-ketoamide substances, and the method comprises the following steps: reacting a compound shown as a formula (A) with a compound shown as a formula (B) in the presence of isoviscin synthetase to obtain alkaloid shown as a formula (C). The method is mild in condition, free of pollution and simple in process route.

The invention discloses an SERS (Surface Enhanced Raman Scattering) aptamer sensor based on a double-layer core-satellite magnetic gold nanostructure and a method for detecting biogenic amine in food by using the SERS aptamer sensor. The Fe3O4 (at) Au MNPs nanoparticles are combined with a nucleic acid aptamer, and a specific magnetic capture probe is obtained; the method comprises the following steps: mixing gold nanoparticle solutions with different particle sizes with 4-MBN, incubating to obtain a'biological silence zone 'SERS tag, and combining the'biological silence zone' SERS tag with pretreated sulfydryl modified c-DNA to obtain a specific SERS signal probe; and oscillating and incubating the specific SERS signal probe solution and the specific magnetic capture probe solution to obtain the SERS aptamer sensor based on the double-layer core-satellite magnetic gold nanostructure. According to the method, a'biological silence zone 'SERS label is combined with a magnetic induction technology, so that the problems of poor anti-interference performance and poor accuracy during detection of trace components in a complex matrix by SERS are solved, and high-efficiency detection of tryptamine in biogenic amine is realized.

The disclosure relates to a compound of formula (1):The disclosure also relates to a compound of formula (Ia):The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I) or formula (Ia) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) or formula (Ia) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formula (I) or formula (Ia).

The present invention relates to inhalable formulations, and kits and methods suitable for the preparation of such inhalable formulations. The inhalable formulations comprise a freebase of a deuterium-substituted dimethyltryptamine compound. The inhalable formulations also comprise a biocompatible excipient. Such formulations are suitable for inhalation and have uses in the treatment of psychiatric or neurological disorders. Deuterium-substituted dimethyltryptamine compounds may be metabolised more slowly than their protio analogues, allowing for a longer lasting therapeutic effect.

The invention features methods of treating depression in a subject in need thereof by administering to the subject a composition, and kits comprising 5-methoxy-N,N-dimethyltryptamine (5- MeO-DMT) in combination with a composition comprising one or more antidepressants, such as a selective serotonin reuptake inhibitor (SSRI), each in an amount that together are sufficient to treat depression in a patient in need thereof.

The application discloses a tryptamine detection method based on triple emission MOFs and a smart phone. A rare earth metal organic framework (AP-Eu) is used as a luminescent matrix, and a fluorescent guest molecule fluorescein-5-isothiocyanate (FITC) is post-modified to obtain a ratio fluorescent material with triple emission characteristics. Competitive absorption of ligands and tryptamine, pH response of FITC and hydrogen bonding are used to realize fluorescence signal regulation, and then high-sensitivity and high-selectivity fluorescence recognition of tryptamine is realized. The method is further applied to quantitative detection of tryptamine in beer samples, visualization detection of foam and on-site rapid detection assisted by a mobile phone APP. The application provides a safe and efficient tryptamine detection and fluorescence sensing method, and significantly improves detection accuracy and on-site applicability.

The present disclosure relates to solid forms, such as salts, solvates, cocrystals and polymorphs, of Compound 1 as well as cocrystals of Compound 1 HO. Also disclosed are methods of preparing said solid forms, pharmaceutical compositions comprising the solid forms, and methods of treatment using said solid forms.

The present application relates to the technical field of pharmaceutical chemistry, and particularly relates to application of tryptophanone in prevention and treatment of plant bacteria and part of plant fungi. The present application discloses that natural product tryptophanone can effectively prevent and treat plant bacterial and part of plant fungal diseases. The application of tryptophanone as an agricultural bactericide in plant bacterial diseases has excellent inhibitory effect on rice bacterial leaf blight, rice bacterial leaf streak, citrus canker, cabbage black rot, tomato bacterial spot, kiwi canker, tobacco bacterial wilt, cucumber bacterial angular spot, potato bacterial wilt, soybean bacterial spot, tomato canker and the like. The tryptophanone also shows good inhibitory activity on plant pathogenic fungi such as grapevine Eutypa lata, tobacco alternaria alternata, eggplant verticillium wilt, pepper fusarium wilt, colletotrichum gloeosporioides, tea tree colletotrichum gloeosporioides and sorghum zylosporium.

The invention relates to an ethyl ester type fish oil preparation method based on sulfonic acid resin catalysis, and belongs to the technical field of deep processing of fish oil. Adding the fish oil, absolute ethyl alcohol and the modified sulfonic acid type resin into a reaction kettle for reaction, and standing to obtain an upper layer which is the ethyl ester type fish oil and a lower layer which is the glycerol and the sulfonic acid type resin; heating and condensing the upper-layer ethyl ester type fish oil to recover the absolute ethyl alcohol to obtain the ethyl ester type fish oil; separating and filtering glycerol and sulfonic acid resin on the lower layer, and packaging and selling the glycerol; eluting the filtered sulfonic acid type resin with absolute ethyl alcohol, drying under reduced pressure, and recycling; the modified sulfonic acid type resin is prepared from sodium type resin, food-grade polyethylene glycol, 5-hydroxytryptamine, food-grade gallic acid, food-grade L-cysteine, a food-grade ethanol-water mixed solution and a food-grade citric acid aqueous solution; the prepared ethyl ester type fish oil has the advantages of low acid value, high esterification rate, low free fatty acid content, good fish oil quality, advanced production process and high efficiency.

The present disclosure includes azetidine tryptamines and methods of treating psychiatric disorders with such compounds. Also provided are pharmaceutical compositions comprising azetidine tryptamine.

The present disclosure relates to compositions comprising N, N-dimethyltryptamine or a salt thereof and N, N-dimethyltryptamine or a salt thereof, pharmaceutical compositions comprising a combination of N, N-dimethyltryptamine or a salt thereof and N-acylethanolamine or a salt thereof with at least one pharmaceutically acceptable carrier and / or excipient and their use in a method of treating cerebral ischemia or hypoxia by administering the composition in a therapeutically effective amount to a subject in need thereof.

Disclosed herein are prokaryotic and eukaryotic microbes, including E. coli and S. cerevisiae, genetically altered to biosynthesize tryptamine and tryptamine derivatives. The microbes of the disclosure may be engineered to contain plasmids and stable gene integrations containing sufficient genetic information for conversion of an anthranilate or an indole to a tryptamine. The fermentative production of substituted tryptamines in a whole-cell biocatalyst may be useful for cost effective production of these compounds for therapeutic use.

Disclosed are novel C4-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same, including C4-ether-substituted tryptamine derivative compounds, C4-carbonic ester-substituted tryptamine derivative compounds, C4-polyether substituted tryptamine derivative compounds, and C4-phosphate substituted tryptamine derivative compounds. The pharmaceutical formulations may be used to treat psychiatric disorders.

Various aspects of this disclosure relate to methods to treat health conditions in human patients, comprising administering a therapeutically-effective dose of a neuroplastic agent. Various aspects of this disclosure relate to method to assimilate human patients to prosthetics, comprising administering a therapeutically-effective dose of a neuroplastic agent. In some embodiments, the neuroplastic agent is a tryptamine such as psilocybin or psilocin.

The invention relates to a synthesis method of alkaloid, and discloses a synthesis method of alkaloid (-)-psychotriadine and analogues thereof, and the synthesis method comprises the following steps: taking a tryptamine derivative as an initial raw material, taking an asymmetric Meerwein-Eschenmoser-Claisen rearrangement reaction and a Fischer indolation and Plancher rearrangement reaction as key reactions, and realizing the preparation of (-)-psychotriadine through a nine-step linear synthesis route. The method disclosed by the invention has gram-level amplification capability, and the problem of medicine source bottleneck of a natural sample and homologues thereof in future medicine research can be solved; meanwhile, it is verified through a Luciferase reporter gene experiment that (-)-psychotriadine and tetrahydropsychotriadine have the transcriptional activation activity of LXR [alpha] and LXR [beta], and the (-)-psychotriadine and the tetrahydropsychotriadine show the potential treatment effect on the Alzheimer's disease.

Various aspects of this disclosure relate to the discovery that phosphatase and laccase enzymes confound the extraction and quantification of psilocybin and other tryptamines during the preparation of psilocybin-containing products from mushrooms. Various aspects of this disclosure relate to the discovery that ionization states of phosphoryloxytryptamines affect the extraction and quantification of psilocybin and other tryptamine. This disclosure describes methods to denature enzymes, optimize ionization states, and control for other variables to improve extraction yields of tryptamines from mushrooms, manufacturing intermediates, and tryptamine-containing products and to improve the accuracy of methods to quantify tryptamines.

The present disclosure includes azetidinyl tryptamines and methods of using such compounds to treat psychiatric disorders. Also provided are pharmaceutical compositions comprising azetidinyl tryptamines.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

The disclosure relates to forms of 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate, including solvates such as methanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (also referred to as 4-glutarato-N,N-diisopropyltryptamine methanol solvate or 4-glutarato-DiPT·MeOH), and crystalline forms thereof such as crystalline form 1 of 4-glutarato-DiPT·MeOH and ethanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (4-glutarato-N,N-diisopropyltryptamine ethanol solvate or 4-glutarato-N,N-DiPT·EtOH), crystalline 4-glutarato-N,N-DiPT·EtOH, and crystalline forms thereof, including crystalline form 1 of 4-glutarato-N,N-DiPT·EtOH; and to pharmaceutical compositions containing them and to methods of treatment using them. The disclosure further relates to crystalline [3-[2-(methylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate (baeocystin), such as crystalline form 1 of baeocystin, and to pharmaceutical compositions containing crystalline baeocystin, such as crystalline form 1 of baeocystin, and to methods of treatment using it.

Pharmaceutical compositions are described that include amorphous N-N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt or prodrug thereof and a polymeric carrier. These compositions are suitable for buccal or sublingual administration to patients. Methods for treating disorders, including neurological disorders, by administering these compositions are described.

The disclosure relates to (2-{4-[(2,2-dimethylpropanoyl)oxy]-1H-indol-3-yl}ethyl)(methyl)azanium chloride (4-pivaloyloxy-N-methyltryptammonium chloride), crystalline 4-pivaloyloxy-N-methyltryptammonium chloride, and specific crystalline forms thereof, including crystalline form 1 of 4-pivaloyloxy-N-methyltryptammonium chloride, to compositions containing the same, and to methods of treatment using them.

There is disclosed a compound of Formula (I):and any pharmaceutically acceptable salt or zwitterion thereof, wherein: R is hydrogen, methyl or ethyl; R1 is hydrogen or C1-C2 alkoxy; R2 is methyl or a C2-C4 group which may be saturated or unsaturated, branched or linear; and R3, R4, R5 and R6 each are independently selected from hydrogen, hydroxyl, halogen, methyl optionally substituted with hydroxy, methoxy, ethoxy, and a saturated or unsaturated C2-C3 that may be optionally substituted with hydroxyl, with the provisos that: (i) at least two of R4, R5, R6 and R7 must be hydrogen, and (ii) R3, R4, R5 and R6 may be selected such that an adjacent pair thereof join to form a ring having at least 5 members. The compound of Formula (I) is believed useful in treating a disease or disorder in a subject which may be alleviated by a 5HT2A agonist (e.g., CNS disorders and one or more symptoms of any one of depression, alcoholism, tobacco addiction, cocaine addiction, inflammation, cluster headache and PTSD in a subject).